Ms. Cai from Jiangxi signed her name on the company's "stay in Hangzhou" list. This Spring Festival is in Hangzhou. In July 2021, she followed hundreds of villagers to the production plant of Aikang biology in Hangzhou and became an ordinary member of the nucleic acid detection medical product production line. It was originally planned to end the "temporary" work and go home for the new year before the Spring Festival in 2022. Unexpectedly, near the end of the year, the order volume in the factory increased greatly, giving employees favorable conditions for "staying in Hangzhou" for the new year. "Plus the subsidy, 31 yuan / hour, there will be a new year red envelope. Work 12 hours a day, at least 300 hours a month, and the monthly salary can exceed 10000." After calculating, Ms. Cai, who is in her 40s, said, "I have not had such a high salary for working for so many years. I want to seize this opportunity." On January 6, flowflex? The COVID-19 self test reagent product was approved by the Australian pharmaceutical regulatory agency TGA and entered the Australian medical products registration list (ARTG). The official website of Aikang biology shows that at present, flowflex? COVID-19 antigen detection reagent has been authorized by FDA EUA, European Union CE and Australia TGA. At the beginning of the new year, the epidemic situation in many parts of the world is high, the number of overseas confirmed cases is rising, and the epidemic situation is becoming more and more serious. Recently, overseas demand for COVID-19 detection kit appeared a "hard box" phenomenon. It is reported that the price of the two dose quick screening kit commonly used in the United States is $14 ~ 24. Now, due to the shortage of supply, the price has doubled several times in some markets. At the same time, there are many local cases in Shaanxi, Henan and Tianjin. Among them, Omicron's raid on Tianjin has spread for at least three generations. Anyang, Henan is also the same transmission chain, which exacerbates the tension. Rapid detection of large scale COVID-19 nucleic acid detection is still an essential part in the epidemic prevention. Repeated global epidemics have busy Chinese workers. Foreign test kits "hard to find" The novel coronavirus pneumonia novel coronavirus pneumonia was released by Johns Hopkins University in the US. At the 6 p.m. est in January 9th, 60062077 cases of new crown pneumonia were reported in the United States, and 837504 cases died. As of the past week on the 9th, the average number of newly confirmed cases in the United States has exceeded 700000. Eight Americans test positive for new crowns every second. In the past five days, the number of newly confirmed cases in the United States has reached a new high in a single day. In fact, by the end of 2021, Omicron had landed all over the United States, and the detection scale in the United States had increased fourfold. Unlike in China, when the epidemic comes, all residents can quickly go to the nearest detection point for nucleic acid detection. In foreign countries, due to the wide spread and long appointment time, buying a rapid detection kit that can be used at home has become the choice of many Americans. Lin Lin, who works in the US, told the first finance company that because of the rapid spread of the epidemic and the long detection time of nucleic acid reservation, many American families will buy COVID-19 testing agents to detect their family members in order to detect the health of family members in time. If the elderly or children at home are inconvenient to go out, they will also use this method to measure themselves. The epidemic situation in Britain is not optimistic. The average daily confirmed cases in Britain in the past week (January 4-9) are about 180000, and there is a serious shortage of new crown detection agents. At present, in the UK, only one manufacturer of local COVID-19 detection kits has passed the government's approval of the new crown detection device. In Australia, novel coronavirus pneumonia cases were diagnosed in Australia alone in January 8th, exceeding 100 thousand cases, and refreshed for many consecutive days. The Australian medical system is under pressure and the testing center is overwhelmed. It is understood that the Biden government signed an agreement with Wal Mart, Kroger and Amazon last summer to sell the binaxnow test kit developed by Abbott at a low price of US $14 (about 89.3 yuan). The kit usually contains two quick screening, which is the most widely used COVID-19 test kit in the United States. The low price sale agreement expired in December 2021. Wal Mart previously said it would raise the price to $19.98 and Kroger's price to $23.99. But Amazon is temporarily out of stock, and the rapid detection kit is "hard to find". Foreign production capacity is insufficient and depends heavily on imports from China In 2020, the British government invested millions of pounds to launch a "moon landing operation", determined to become the world's leading manufacturer of new crown testing agents. With the strong support of the government, British manufacturers have invested in research. However, nearly two years later, only one manufacturer named "surescreen" has passed the government's "approval of new crown detection device". British Omega testing company was also fined for signing a huge contract worth 374 million pounds with the government, but failed to pass the government's approval. At present, the new crown detection kit in the UK mainly relies on Zhejiang Dongfang gene biological products Co., Ltd. and Aikang biology. The detection tool providers in Australia are also mainly from enterprises in Zhejiang and Jiangsu in China. The new crown test agent in the United States mainly comes from the binaxnow test kit developed by the domestic manufacturer Abbott, as well as Aikang biology and Jiuan medical (002432. SZ) in China. The price of ihealth test agent produced by Jiuan medical on Amazon, an American e-commerce platform, is only $6.99, but it has long been fully sold out. Since the emergence of the Omicron mutant in November last year, the global demand for China's new crown testing agent began to increase greatly. According to China's customs data, from the perspective of export market, China's neocrown antigen reagents were mainly sold to Germany, the United Kingdom, the United States, Canada and Greece in November 2021. Among them, Germany imported 1.308 billion yuan in November, an increase of 179.24% month on month, surpassing Britain as the largest importer of new crown testing reagents in China. The import volume of Britain and the United States ranked second and third, reaching 715 million yuan and 346 million yuan respectively, with a month on month increase of 27.58% and 179.24% respectively. At the end of 2021, the chief health officer of Australia suggested that the use of rapid antigen detection should be increased, including the monitoring of transmission in essential workers and high-risk environments. Rapid antigen detection may become a key measure to curb the large-scale outbreak of the epidemic and reduce the pressure of nucleic acid detection. Wu Tong, Secretary of the board of directors of Jiuan medical, revealed at the research meeting on December 29, 2021 that the company's current monthly production capacity is 100 million people. It is estimated that the production capacity will increase to 200 million people per month by the beginning of 2022. As of December 27, U.S. time, Jiuan medical has received 47.43 million government orders from Massachusetts, California, New York, Washington, D.C., Washington, Louisiana, Maryland and Oregon. At present, 8.82 million people have been shipped. Anxin securities predicts that with the spread of Omicron mutant, the further promotion of home self inspection products in the United States and the upcoming spring semester in January, it will continue to stimulate the demand for new crown testing. Based on the judgment of future industry trends, it is expected that the total market size of Xinguan testing in Europe and the United States is expected to reach US $3.391 billion in 2022. Domestic demand for COVID-19 has surged From the domestic point of view, with the reports of local cases in Shaanxi, Henan and Tianjin, large-scale detection of COVID-19 nucleic acid is being carried out one by one. In the early morning of December 22, 2021, under the dispatch of the National Health Commission, Jinyu medicine urgently invested two groups of five cabin in one "Falcon" hard gas membrane laboratory in Xi'an, located in Xi'an International Convention and Exhibition Center, which is responsible for undertaking the nucleic acid samples screened by the whole staff in Xi'an. The hard gas membrane laboratory can detect up to 250000 tubes of nucleic acid samples per day. According to the 10 mixed 1 sampling method, it can detect up to 2.5 million people per day. Henan and Tianjin have also started full nucleic acid testing to combat the epidemic. Jinyu medicine told first finance that Tianjin, Zhengzhou and other places are deploying production capacity according to the needs of local governments. As a manufacturer, Daan gene also said on the interactive platform that the company's new crown nucleic acid detection kit is available to many provinces, cities and regions in China, including Xi'an. "Up to now, 11744 medical and health institutions in China can carry out nucleic acid detection. Our overall nucleic acid detection capacity has reached 29.95 million copies per day. If we are equipped with the '10 mixed 1' detection method, our detection capacity can be doubled." Guo Yanhong, supervisor of the medical administration of the National Health Commission, said at the press conference of the joint prevention and control mechanism of the State Council on December 11. The advantage of made in China highlights the overtime rush in spring "There is no change in the sensitivity and specificity of mainstream nucleic acid detection reagents in China, which can cope with the input of Omicron mutant." Xu Wenbo, director of the Institute of virus prevention and control of China CDC, said at the press conference of the joint prevention and control mechanism of the State Council held on November 30, 2021. At present, many new crown detection biological companies such as Wanfu biological (300482. SZ), Dongfang biological (688298. SH) and Antu biological (603658. SH) have said that their listed products will not miss the detection and miss the target of Omicron mutant. Customs statistics show that in November 2021, the export value of diagnostic reagents (mainly neocrown antigen reagents) with HS code 30021500 in China reached 4.165 billion yuan, an increase of 80.62% month on month in October, the first month on month increase after six consecutive months of decline. According to provinces, Zhejiang's export volume increased greatly, which was the main reason for the increase of the overall export volume of new crown antigen reagent in November. In November, the export value of Zhejiang new crown antigen reagent reached 2.424 billion yuan, an increase of 54.35% month on month. In that month, the export value of Zhejiang accounted for 58.21% of the total export value of China's new crown antigen reagent, ranking first in China. The export volume of other major export provinces of new crown reagent also increased significantly. Among them, the export of new crown antigen reagent in Beijing in November was 506 million yuan, an increase of 146.98% month on month; In November, the export of new crown antigen reagent in Fujian was 491 million yuan, an increase of 137.32% month on month; In November, Guangdong exported 290 million yuan of new crown antigen reagent, an increase of 94.80% month on month. The growth of overseas orders makes the front-line general workers busy. Ms. Cai introduced to China first finance and economics that after entering the factory in the second half of last year, she basically worked for 12 hours every day. If she is lucky, she can rest one day a week. Sometimes she can only rest one day in half a month or a month in case of rush. After entering November, the factory put forward preferential conditions for employees to "stay in Hangzhou" for the new year. As can be seen from the welfare notice of staying in Hangzhou displayed by Ms. Cai, the salary of employees who do not go home during the new year can be increased from the original 21 yuan / hour to 31 ~ 35 yuan / hour. At the same time, there is a reward of 6000 yuan, and the comprehensive income will reach 11000 yuan / month. The high wages were maintained for three months, December, January and February. Work 12 ~ 13 hours a day, 26 ~ 28 days a month. "More than 100 people in our hometown basically stayed in the factory." Ms. Cai said with a smile, "if it goes well, I'll go home for the new year on May Day next year." (Xinhua News Agency)